Who
Sergio Traversa
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Relmada Therapeutics; Interim CFO, Actinium Pharmaceuticals, Inc. (Delaware).
In numbers
- Trades disclosed
- 114
- Buys
- 21
- Sells
- 15
- Bought
- $3.7M
- Sold
- $2.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Aug 2013
- Last trade
- 10 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $410K100,000 at $4.10 | filing |
| 10 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $410K100,000 at $4.10 | filing |
| 9 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $418K100,000 at $4.18 | filing |
| 9 Sep 2026filed 11 Sep 2026 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $418K100,000 at $4.18 | filing |
| 15 Dec 2025filed 16 Dec 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $113K27,500 at $4.12 | filing |
| 12 Dec 2025filed 16 Dec 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,198,000 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $600K272,500 at $2.20 | filing |
| 28 Aug 2025filed 28 Aug 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $41K55,976 at $0.74 | filing |
| 27 Aug 2025filed 28 Aug 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $87K129,455 at $0.67 | filing |
| 26 Aug 2025filed 28 Aug 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K80,545 at $0.62 | filing |
| 26 Jun 2025filed 30 Jun 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 20 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $83K147,686 at $0.56 | filing |
| 19 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K30,000 at $0.50 | filing |
| 16 May 2025filed 20 May 2025 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $78K172,314 at $0.45 | filing |
| 11 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $154K51,407 at $2.99 | filing |
| 10 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $91K33,014 at $2.75 | filing |
| 9 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $151K55,579 at $2.71 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —122,358 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —122,358 at $0.00 | filing |
| 31 Jan 2024filed 31 Jan 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $110K27,460 at $4.00 | filing |
News
No headline names them, or the companies they trade most, lately.